Mesoblast (NASDAQ:MESO) received a $16.00 price objective from research analysts at Oppenheimer in a research report issued to clients and investors on Wednesday, December 20th. The firm currently has a “buy” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 171.65% from the stock’s previous close. Oppenheimer also issued estimates for Mesoblast’s FY2020 earnings at $1.15 EPS and FY2021 earnings at $2.70 EPS.
A number of other brokerages also recently issued reports on MESO. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Mesoblast in a research report on Wednesday, August 30th. Maxim Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Mesoblast in a research report on Tuesday, September 26th. ValuEngine downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. CIBC initiated coverage on shares of Mesoblast in a research report on Thursday, August 31st. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Mesoblast has an average rating of “Hold” and a consensus price target of $13.11.
Mesoblast (MESO) opened at $5.89 on Wednesday. The company has a market cap of $537.63, a PE ratio of -7.18 and a beta of 2.44. Mesoblast has a 12-month low of $4.80 and a 12-month high of $12.50.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/01/13/mesoblast-meso-given-a-16-00-price-target-by-oppenheimer-analysts.html.
Mesoblast Company Profile
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.